Detalhe da pesquisa
1.
Characterization of a potent and highly unusual minimally enhancing antibody directed against dengue virus.
Nat Immunol
; 19(11): 1248-1256, 2018 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-30323338
2.
Germline bias dictates cross-serotype reactivity in a common dengue-virus-specific CD8+ T cell response.
Nat Immunol
; 18(11): 1228-1237, 2017 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-28945243
3.
Dengue virus sero-cross-reactivity drives antibody-dependent enhancement of infection with zika virus.
Nat Immunol
; 17(9): 1102-8, 2016 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-27339099
4.
A new class of highly potent, broadly neutralizing antibodies isolated from viremic patients infected with dengue virus.
Nat Immunol
; 16(2): 170-177, 2015 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-25501631
5.
Heterologous prime-boost immunization induces protection against dengue virus infection in cynomolgus macaques.
J Virol
; 97(11): e0096323, 2023 Nov 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-37846984
6.
Comparison of the reactogenicity and immunogenicity between two-dose mRNA COVID-19 vaccine and inactivated COVID-19 vaccine followed by an mRNA vaccine in children aged 5-11 years.
J Med Virol
; 95(5): e28758, 2023 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-37212319
7.
Neutralizing Activities Against the Omicron Variant After a Heterologous Booster in Healthy Adults Receiving Two Doses of CoronaVac Vaccination.
J Infect Dis
; 226(8): 1372-1381, 2022 10 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-35267040
8.
Corrigendum: A new class of highly potent, broadly neutralizing antibodies isolated from viremic patients infected with dengue virus.
Nat Immunol
; 16(7): 785, 2015 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-26086146
9.
Corrigendum: A new class of highly potent, broadly neutralizing antibodies isolated from viremic patients infected with dengue virus.
Nat Immunol
; 16(5): 544, 2015 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-25898199
10.
Effects of boosted mRNA and adenoviral-vectored vaccines on immune responses to omicron BA.1 and BA.2 following the heterologous CoronaVac/AZD1222 vaccination.
J Med Virol
; 94(12): 5713-5722, 2022 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-35924475
11.
Omicron BA.1, BA.2 and COVID-19 Booster Vaccination.
J Infect Dis
; 226(8): 1480-1481, 2022 10 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-35481828
12.
Structural analysis of a dengue cross-reactive antibody complexed with envelope domain III reveals the molecular basis of cross-reactivity.
J Immunol
; 188(10): 4971-9, 2012 May 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-22491255
13.
The alteration of NK cells phenotypes related to the functions and dengue disease outcomes.
Virus Res
; 345: 199382, 2024 May 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-38697295
14.
Immunogenicity and durability against Omicron BA.1, BA.2 and BA.4/5 variants at 3-4 months after a heterologous COVID-19 booster vaccine in healthy adults with a two-doses CoronaVac vaccination.
Heliyon
; 10(1): e23892, 2024 Jan 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-38226248
15.
Long-Term Dynamic Changes in Hybrid Immunity over Six Months after Inactivated and Adenoviral Vector Vaccination in Individuals with Previous SARS-CoV-2 Infection.
Vaccines (Basel)
; 12(2)2024 Feb 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-38400163
16.
Immunodominant T-cell responses to dengue virus NS3 are associated with DHF.
Proc Natl Acad Sci U S A
; 107(39): 16922-7, 2010 Sep 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-20837518
17.
Dynamic Antibody Response and Hybrid Immunity Following Multiple COVID-19 Vaccine Doses and Infection: A Case Study.
Cureus
; 15(9): e45531, 2023 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-37731681
18.
Neutralizing antibodies against Omicron BA.5 among children with infection alone, vaccination alone, and hybrid immunity.
Int J Infect Dis
; 134: 18-22, 2023 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-37207716
19.
Blockade-of-Binding Activities toward Envelope-Associated, Type-Specific Epitopes as a Correlative Marker for Dengue Virus-Neutralizing Antibody.
Microbiol Spectr
; 11(4): e0091823, 2023 08 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-37409936
20.
Safety and immunogenicity of intradermal administration of fractional dose CoronaVac®, ChAdOx1 nCoV-19 and BNT162b2 as primary series vaccination.
Front Immunol
; 13: 1010835, 2022.
Artigo
em Inglês
| MEDLINE | ID: mdl-36268028